Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial.

Abdel-Rahman O.

Clin Genitourin Cancer. 2019 Aug;17(4):e837-e844. doi: 10.1016/j.clgc.2019.05.015. Epub 2019 May 25.


Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer.

Schoen RE, Razzak A, Yu KJ, Berndt SI, Firl K, Riley TL, Pinsky PF.

Gastroenterology. 2015 Nov;149(6):1438-1445.e1. doi: 10.1053/j.gastro.2015.07.055. Epub 2015 Aug 5.


Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.


Risk of childhood mortality in family members of men with poor semen quality.

Hanson HA, Mayer EN, Anderson RE, Aston KI, Carrell DT, Berger J, Lowrance WT, Smith KR, Hotaling JM.

Hum Reprod. 2017 Jan;32(1):239-247. Epub 2016 Dec 6.


Deep Learning to Assess Long-term Mortality From Chest Radiographs.

Lu MT, Ivanov A, Mayrhofer T, Hosny A, Aerts HJWL, Hoffmann U.

JAMA Netw Open. 2019 Jul 3;2(7):e197416. doi: 10.1001/jamanetworkopen.2019.7416.


Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team.

J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.


Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.

Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, Commins J, Berg CD.

PLoS Med. 2014 Dec 2;11(12):e1001764. doi: 10.1371/journal.pmed.1001764. eCollection 2014 Dec. Erratum in: PLoS Med. 2015 Jan;12(1):e1001787.


Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.


Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening.

Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK.

J Urol. 2015 Jan;193(1):75-9. doi: 10.1016/j.juro.2014.07.085. Epub 2014 Jul 24.


Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.


Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.

Pierre-Victor D, Pinsky PF.

JAMA Intern Med. 2019 Feb 1;179(2):196-203. doi: 10.1001/jamainternmed.2018.5982.


Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.

Pinsky PF, Parnes HL, Andriole G.

BJU Int. 2014 Feb;113(2):254-9. doi: 10.1111/bju.12368. Epub 2013 Nov 21.


Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.


Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Black A, Parnes HL, Grubb R, David Crawford E, Miller A, Reding D, Andriole G.

Cancer Epidemiol. 2012 Dec;36(6):e401-6. doi: 10.1016/j.canep.2012.08.008. Epub 2012 Sep 19.


Randomization to screening for prostate, lung, colorectal and ovarian cancers and thyroid cancer incidence in two large cancer screening trials.

O'Grady TJ, Kitahara CM, DiRienzo AG, Boscoe FP, Gates MA.

PLoS One. 2014 Sep 5;9(9):e106880. doi: 10.1371/journal.pone.0106880. eCollection 2014.


Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.

Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):101-110. doi: 10.1016/S2468-1253(18)30358-3. Epub 2018 Nov 29.


Concentrated sugars and incidence of prostate cancer in a prospective cohort.

Miles FL, Neuhouser ML, Zhang ZF.

Br J Nutr. 2018 Sep;120(6):703-710. doi: 10.1017/S0007114518001812. Epub 2018 Jul 26.


Outcomes of Prostatectomy versus Radiation Therapy in the Management of Clinically Localized Prostate Cancer Patients Within the PLCO Trial.

Abdel-Rahman O.

Clin Genitourin Cancer. 2019 Apr;17(2):e329-e338. doi: 10.1016/j.clgc.2018.12.010. Epub 2019 Jan 4.


Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD; PLCO Project Team.

J Natl Cancer Inst. 2010 May 19;102(10):722-31. doi: 10.1093/jnci/djq126. Epub 2010 May 4.


Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study.

Quintero E, Carrillo M, Leoz ML, Cubiella J, Gargallo C, Lanas A, Bujanda L, Gimeno-García AZ, Hernández-Guerra M, Nicolás-Pérez D, Alonso-Abreu I, Morillas JD, Balaguer F, Muriel A; Oncology Group of the Asociación Española de Gastroenterología (AEG).

PLoS Med. 2016 May 3;13(5):e1002008. doi: 10.1371/journal.pmed.1002008. eCollection 2016 May.

Supplemental Content

Support Center